Extraordinary General Meeting of Shareholders to Approve Business Combination Scheduled for May 27, 2026BOSTON and NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Factorial Inc. (“Factorial” or the ...
So, the natural question for Cartesian Therapeutics (NASDAQ:RNAC) shareholders is whether they should be concerned by its rate of cash burn. In this article, we define cash burn as its annual ...
Secured up to $150 million of non-dilutive financing from K2 HealthVentures; funding of $50 million from initial tranche extends cash runway into ...
Just to go ahead and give everyone a quick refresher, CAR-T treatment aims to reengineer a patient’s T-cells so that they will eliminate harmful B-cells that cause all sorts of problems. To this day, ...
Preliminary Data from Ongoing Phase 2 Open-Label Trial of Descartes-08 in Patients with SLE Expected in the Second Half of 2025. The trial is designed to assess the safety, tolerability and clinical ...
View Cartesian Growth Corp. III Class A CGCT stock quote prices, financial information, real-time forecasts, and company news from CNN.
Detailed price information for Cartesian Therapeutics Inc (RNAC-Q) from The Globe and Mail including charting and trades.
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) on Tuesday revealed 12-month efficacy and safety data from the Phase 2b trial of Descartes-08, lead cell therapy candidate, in participants with generalized ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results